ESR1 and breast carcinoma: Given a clear difference between MCF-7 and MDA-MB-231 cells in terms of the expression level of ER (24, 30), our results further suggested potential usefulness of both Helle and Areno in developing therapeutic strategies to treat patients with different types of breast cancer, especially ER-positive breast cancer.